[1] RAGHU G, COLLARD H R, EGAN J J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management [J]. Am J Respir Crit Care Med, 2011, 183(6):788-824.
[2] WOODCOCK H V, MAHER T M. The treatment of idiopathic pulmonary fibrosis [J]. F10000 Prime Rep, 2014, 6(1):16.
[3] ROSENBLOOM J, MENDOZA F A, JIMENEZ S A. Strategies for anti-fibrotic therapies [J]. Biochim Biophys Acta, 2013, 1832 (7):1088-1103.
[4] SANTIBAEZ J F, QUINTANILLA M, BERNABEU C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions [J]. Clin Sci (Lond), 2011, 121 (6):233-251.
[5] FERNANDEZ I E, EICKELBERG O. The impact of TGF-β on lung fibrosis: From targeting to biomarkers [J]. Proc Am Thorac Soc, 2012, 9 (3):111-116.
[6] CHERESH P, KIM S J, TULASIRAM S, et al. Oxidative stress and pulmonary fibrosis [J]. Biochim Biophys Acta, 2013, 1832 (7):1028-1040.
[7] ZHONG C J, LI L, LI J, et al. The role and mechanisms of oxidative stress in idiopathic pulmonary fibrosis [J]. Chin Pharmacol Bull(中国药理学通报), 2012, 28(2):169-172.
[8] JIANG F, LIU G S, DUSTING G J, et al. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses[J]. Redox Biol, 2014, 2(1):267-272.
[9] CARNESECCHI S, DEFFERT C, DONATI Y, et al. A key role for NOX4 in epithelial cell death during development of lung fibrosis [J]. Antioxid Redox Signal, 2011, 15(3):607-619.
[10] JARMAN E R, KHAMBATA V S, COPE C, et al. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model [J]. Am J Respir Cell Mol Biol, 2014, 50(1):158-169.
[11] KAGE H, BOROK Z. EMT and interstitial lung disease: A mysterious relationship [J]. Curr Opin Pulm Med, 2012, 18 (5):517-523.
[12] CHAPMAN H A. Epithelial-mesenchymal interactions in pulmonary fibrosis[J]. Annu Rev Physiol, 2011, 73(1):413-435.
[13] NOWRIN K, SOHAL S S, PETERSON G, et al. Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: Fibrosis, remodeling and cancer [J]. Expert Rev Respir Med, 2014, 8 (5):547-559.
[14] DERYNCK R, MUTHUSAMY B P, SAETEURN K Y. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition[J]. Curr Opin Cell Biol, 2014, 31:56-66.
[15] SHEN H J, SUN Y H, ZHANG S J, et al. Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation [J]. Biochim Biophys Acta, 2014, 1840 (6):1838-1849.
[16] ABDALLA M, SABBINENI H, PRAKASH R, et al. Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGF-β-induced pulmonary fibrosis [J]. Br J Pharmacol, 2015, 172(16):4173-4188.
[17] CHEN H H, ZHOU X L, SHI Y L, et al. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition [J]. Arch Med Res, 2013, 44 (2):93-98.
[18] KOLOSOVA I, NETHERY D, KERN J A. Role of Smad2/3 and p38 MAP kinase in TGF-β1-induced epithelial-mesenchymal transition of pulmonary epithelial cells [J]. J Cell Physiol, 2011, 226 (5):1248-1254.
[19] MA Z, PAN Y L, HUANG W H, et al. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents [J]. Bioorg Med Chem Lett, 2014, 24 (1):220-223.
[20] CLARKE D L, CARRUTHERS A M, MUSTELIN T, et al. Matrix regulation of idiopathic pulmonary fibrosis: The role of enzymes [J]. Fibrogenesis Tissue Repair, 2013, 6 (1):20.
[21] PARK S A, KIM M J, PARK S Y, et al. EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling [J]. Cell Mol Life Sci, 2015, 72 (10):2023-2039.
[22] SATISH L, GALLO P H, BARATZ M E, et al. Reversal of TGF-β1 stimulation of a-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren′s-derived fibroblasts [J]. BMC Musculoskelet Disord, 2011, 12:113.
[23] BLAAUBOER M E, BOEIJEN F R, EMSON C L, et al. Extracellular matrix proteins: A positive feedback loop in lung fibrosis [J]. Matrix Biol,2014, 34(4):170-178.
[24] JI H, TANG H, LIN H, et al. Rho/Rock cross-talks with transforming growth factor-β/Smad pathway participates in lung fibroblast-myofibroblast differentiation [J]. Biomed Rep, 2014, 2 (6):787-792.
[25] SRIRAM N, SRINIVASAN K, MANIKANDAN R, et al. Epigallocatechin gallate attenuates fibroblast proliferation and excessive collagen production by effectively intervening TGF-β1 signaling [J]. Clin Exp Pharmacol Physiol, 2015, 42(8):849-859.
[26] HUANG M S, LIU J B, SU X, et al. Effects of spearmint oil on mice with pulmonary fibrosis induced by bleomycin and its impact on the expression of α-SMA [J]. Chin Pharm J(中国药学杂志), 2012, 47 (7):504-512.
[27] BORTHWICK L A, WYNN T A, FISHER A J. Cytokine mediated tissue fibrosis [J]. Biochim Biophys Acta, 2013, 1832 (7):1049-1060.
[28] HUANG M, YANG H, ZHU L, et al. Inhibition of connective tissue growth factor attenuates paraquat-induced lung fibrosis in a human MRC-5 cell line [J]. Environ Toxicol,2015, doi:10.1002/tox.22166.
[29] SONNYLALl S, XU S, JONES H, et al. Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro [J]. J Cell Sci, 2013, 126 (10):2164-2175.
[30] PAN Y L, HUANG W H, SHEN Z R, et al. Mechanism and progress in treatment of pulmonary fibrosis [J]. Chin Pharm J(中国药学杂志),2012,47 (23):1873-1876.
[31] ANDRIANIFAHANANA M, WILKES M C, GUPTA S K, et al. Profibrotic TGF-β responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases [J]. FASEB J, 2013, 27(11):4444-4454.
[32] DENG X, JIN K, LI Y, et al. Platelet-derived growth factor and transforming growth factor β1 regulate ARDS-associated lung fibrosis through distinct signaling pathways [J]. Cell Physiol Biochem, 2015, 36 (3):937-946.
[33] YAN Z, KUI Z, PING Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis [J]. Autoimmun Rev, 2014, 13 (10):1020-1025.
[34] LIPSON K E, WONG C, TRNG Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis[J]. Fibrogenesis Tissue Repair, 2012, 5(suppl 1):24.
[35] NORMAN P. Evaluation of WO2013117503 and WO2013117504: The use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis [J]. Expert Opin Ther Pat, 2014, 24(6): 719-722.